Caris Life Sciences, Inc. 4

David D. Halbert had 40,712 Caris Life Sciences, Inc. common shares withheld at $15.25 per share to cover taxes on RSU vesting, leaving 2,574,533 shares held directly and significant additional indirect holdings.

On May 15, 2026, David D. Halbert, Founder, Chairman, and Chief Executive Officer of Caris Life Sciences, Inc., had 40,712 shares of common stock withheld by the company at an implied price of $15.25 per share (approximately $621,000 in value) to satisfy tax obligations arising from the vesting and settlement of restricted stock units (RSUs). This is reported as a code "F" transaction (payment of tax liability by withholding securities) and reduces his directly held shares to 2,574,533, while he continues to be deemed to beneficially own a much larger indirect stake of 121,025,002 shares held through various affiliated entities and family investment vehicles, over which he has voting and investment power but disclaims beneficial ownership beyond his pecuniary interest.

Filing Facts

CIK

2019410

Ticker

CAI

Form

4

Source Type

fda

Accession

0001034380-26-000004

Alert Tier

5